Skip to content
Titan Biotech logo

Titan Biotech

524717 BSE
₹322.75

Close ·

P/E
39.31
View as Markdown
MCP
Close 4 Nov 2026 ₹322.75 +163.99 +103% 1Y
Start ₹158.76

Key Fundamentals

MicrocapChemicals & PetrochemicalsChemicals

Price-based figures at the close · EPS basis: Consolidated · TTM

ROCE
22.80%
Debt to Equity
0.03
EPS (TTM)
₹8.21
Book Value
₹35.15
Market Cap
—
P/E (TTM)
39.31
P/B
9.18
ROE
17.80%
Dividend Yield
0.15%
EBITDA
₹44.00 Cr
52W High
₹444.52
52W Low
₹137.12

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

57 Good

Data confidence 100/100

Category scores

Quality
83
Strong
Returns, margins, earnings quality 22% weight
Valuation
19
Poor
Cheap vs sector & own history 24% weight
Growth
94
Strong
Sales & profit trajectory 9% weight
Financial Health
90
Strong
Solvency, leverage, coverage 9% weight
Momentum
38
Weak
Trend strength, vol-adjusted 12% weight
Ownership
51
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company is expected to give good quarter

Weaknesses

2
  • Stock is trading at 8.72 times its book value
  • The company has delivered a poor sales growth of 7.71% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish964
OscillatorsBearish261
Moving AveragesStrong Bearish703

Key readings

RSI (14)
47.92
Neutral
MACD (12,26,9)
3.10
Bearish
SMA (50)
323.34
Bearish
SMA (200)
307.61
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+16.17%
5Y+7.72%
3Y+12.68%
1Y+32.05%
TTM+37.74%

Net profit

Net profit growth by window
10Y+31.10%
5Y−1.28%
3Y+6.27%
1Y+36.36%
TTM+59.09%

Operating cash flow

Operating cash flow growth by window
10Y+19.62%
5Y+9.57%
3Y+12.62%
1Y+50.00%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+10.23 pp
5Y−13.46 pp
3Y−1.90 pp
1Y+2.90 pp
TTM+2.20 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹53.00 Cr
Mar 2018₹57.00 Cr
Mar 2019₹65.00 Cr
Mar 2020₹79.00 Cr
Mar 2021₹142 Cr
Mar 2022₹124 Cr
Mar 2023₹144 Cr
Mar 2024₹164 Cr
Mar 2025₹156 Cr
Mar 2026₹206 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹2.00 Cr
Mar 2018₹3.00 Cr
Mar 2019₹4.00 Cr
Mar 2020₹8.00 Cr
Mar 2021₹32.00 Cr
Mar 2022₹22.00 Cr
Mar 2023₹25.00 Cr
Mar 2024₹25.00 Cr
Mar 2025₹22.00 Cr
Mar 2026₹30.00 Cr

Quarterly Results

₹ Cr
524717 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
35
43
46
40
43
40
38
35
46
54
57
49
59
Expenses
27
35
35
33
35
32
33
31
38
45
46
39
47
Operating Profit
8
9
11
7
8
8
5
5
9
9
11
10
12
OPM %
23%
20%
23%
18%
19%
19%
13%
13%
19%
17%
19%
20%
21%
Other Income
0
1
0
0
1
0
2
1
1
1
1
2
2
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
1
1
1
1
1
1
1
1
1
1
1
1
1
PBT
7
8
10
6
8
7
5
5
8
9
11
10
13
Tax %
24%
26%
26%
24%
24%
25%
26%
25%
24%
26%
26%
36%
26%
Net Profit
6
7
7
5
6
7
4
4
7
8
9
7
11
EPS (₹)
1.49
1.58
1.74
1.21
1.55
1.62
1.06
0.98
1.66
1.88
2.07
1.63
2.63

Profit & Loss

₹ Cr
524717 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
40
46
53
57
65
79
142
124
144
164
156
206
219
Expenses
36
42
47
50
56
66
96
92
114
130
131
168
176
Operating Profit
4
4
5
7
9
13
46
31
30
34
25
39
42
OPM %
10%
9%
10%
12%
14%
17%
32%
25%
21%
21%
16%
19%
19%
Other Income
0
1
0
0
1
1
0
1
2
2
4
5
6
Interest
1
1
1
2
2
2
2
1
1
1
1
1
1
Depreciation
1
1
1
1
2
2
2
2
3
3
4
5
5
PBT
2
3
3
4
6
10
43
29
28
32
24
38
43
Tax %
33%
34%
35%
35%
30%
25%
26%
25%
25%
25%
25%
28%
—
Net Profit
2
2
2
3
4
8
32
22
25
25
22
30
34
EPS (₹)
0.42
0.46
0.56
0.66
0.85
1.71
7.35
5.25
6.01
6.02
5.21
7.23
8.21
Div. Payout %
36%
33%
27%
23%
0%
12%
4%
6%
6%
7%
8%
7%
—

Balance Sheet

₹ Cr
524717 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
8
8
8
8
8
8
8
8
8
Reserves
13
14
15
17
24
31
60
78
102
125
145
173
Borrowings
8
11
22
26
24
24
16
9
9
8
3
6
Other Liabilities
5
7
7
7
9
13
16
13
16
15
19
27
Total Liabilities
34
40
52
57
65
76
101
108
135
157
175
214
Fixed Assets
11
11
13
14
29
31
34
35
36
52
57
62
CWIP
1
5
9
13
0
0
0
4
13
3
2
2
Investments
0
0
0
0
0
0
0
4
15
28
33
60
Other Assets
21
24
30
30
36
45
67
65
70
74
83
90
Total Assets
34
40
52
57
65
76
101
108
135
157
175
214

Cash Flow

₹ Cr
524717 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−2
5
0
2
5
6
19
22
21
21
20
30
Investing
−3
−5
−8
−6
−4
−2
−5
−16
−21
−20
−10
−33
Financing
3
2
9
0
0
−4
−11
−4
−2
−3
−8
−2
Net Cash Flow
−2
2
1
−3
1
0
4
2
−2
−2
2
−4
Free Cash Flow
−3
0
−7
−4
1
8
14
8
8
12
12
23
CFO/OP
−28
143
21
43
74
62
65
93
97
85
103
101

Ratios

524717 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
58
47
44
49
52
54
46
48
53
42
44
40
Inventory Days
134
118
155
202
236
259
177
206
179
208
243
202
Days Payable
17
18
15
13
24
38
20
25
27
15
36
31
Cash Conversion Cycle
175
147
184
239
264
276
203
230
205
234
250
211
Working Capital Days
94
60
90
108
97
101
88
118
109
111
131
102
ROCE %
—
12%
12%
13%
15%
20%
58%
32%
27%
25%
17%
23%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Titan Biotech insights

60 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 55.78%
  • Public 28.16%
  • Others 16.05%
  • DIIs 0.01%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Titan Biotech

What does Titan Biotech Ltd do?
Incorporated in 1992, Titan Biotech Ltd manufacturer and exporter of the Biological products
Where is Titan Biotech Ltd (TITANBIO) listed?
Titan Biotech Ltd trades under code 524717 on the BSE.
Which sector does Titan Biotech Ltd belong to?
Titan Biotech Ltd is classified under the Chemicals sector, in the Specialty Chemicals industry.
What is the PE ratio of Titan Biotech Ltd?
Titan Biotech Ltd trades at a PE ratio of 39.31 as of 4 Nov 2026, on earnings per share of ₹8.21, against a book value of ₹35.15 per share.
What is the 52-week high and low of Titan Biotech Ltd?
Over the last 52 weeks Titan Biotech Ltd has traded between ₹137.12 and ₹444.52 as of 4 Nov 2026.
Does Titan Biotech Ltd pay dividends?
Titan Biotech Ltd has a dividend yield of 0.15%.
What is the Return on Equity (ROE) of Titan Biotech Ltd?
Titan Biotech Ltd reported a return on equity of 17.80%. Its debt-to-equity ratio is 0.03.

Company Information

Incorporated in 1992, Titan Biotech Ltd manufacturer and exporter of the Biological products

Website titanbiotechltd.com
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524717.md for Titan Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Chemical & Petrochemical stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month